Citable company snapshot
Boston Scientific's latest SEC-sourced 2026-06-30 period shows $5.44B in revenue and $907.00M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 30, 2026 | $5.44B | $5.20B | +4.6% |
| Gross Profit | Jun 30, 2026 | $3.85B | $3.61B | +6.5% |
| Operating Income | Jun 30, 2026 | $1.18B | $1.10B | +7.0% |
| Net Income | Jun 30, 2026 | $907.00M | $1.34B | -32.4% |
| Operating Cash Flow (computed) | Jun 30, 2026 | $1.47B | $348.00M | +323.6% |
| Free Cash Flow (computed) | Jun 30, 2026 | $1.28B | $171.00M | +648.0% |
Source: SEC EDGAR financial statements; period Jun 30, 2026; filed Aug 3, 2026; accession 0000885725-26-000053.
BSX company research is available with Aerarium Pro (CAD $10/mo). The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay free. Already a subscriber? Sign in to pick up where you left off.